Byetta Went Generic First. Nobody Threw a Party.

All eight patents listed for Byetta in the FDA’s Orange Book had expired by January 2020. Byetta is exenatide, the original GLP-1 drug in this whole saga, and you might expect that the end of its patents would be a big moment. It was not. Four and a half years later, on August 16, 2024, AstraZeneca permanently discontinued Byetta, and in December 2024 it discontinued Bydureon BCise, the longer-acting exenatide, which one source summarizes as “eliminating the branded reference product.”

So if you typed exenatide generic into a search engine, here is the plain answer the facts allow. Exenatide was the first GLP-1 molecule to run out of listed US patent protection. But nothing in the sources here shows a generic exenatide product launching in the US, and the drug the trade press calls the first generic GLP-1 was liraglutide, in June 2024. In Canada, DrugPatentWatch estimates the generic entry opportunity date for Bydureon at June 21, 2027. Exenatide went generic first in the legal sense and, as far as anyone has documented, not in the pharmacy sense.

Is there an exenatide generic, or did the patents just expire into silence?

Whether a US generic of Byetta was ever sold is not something these sources settle, and I am not going to guess. What they do settle is the order of events. The patents went first, in 2020. The first generic GLP-1 of any kind came in 2024, and it was a different molecule. Then the exenatide brands were withdrawn.

That is a weird sequence. Usually the story goes patent expires, generics arrive, price falls, everyone writes an article about the cliff. (I write some of those articles, and the cliff metaphor is doing a lot of unpaid labor in them.) Here the patent expired and then, in some sense, the cliff walked away.

The obvious objection: expired patents should mean cheap copies

The sensible reaction is: a patent is a monopoly with an end date, the end date came, so the monopoly should be over and copies should be everywhere. That is basically how small-molecule pills work. The patent lapses, a dozen manufacturers show up, and the price falls a lot.

That objection is correct about the rule. It is wrong about the incentive. A patent expiring does not make anyone launch anything. It just removes one reason not to.

A generic company has to want the market. And the market for a GLP-1 molecule is not a fixed pie that sits around waiting to be copied. It is presumably shrinking or growing based on whatever newer drug doctors prefer, which is stuff no patent office controls.

Here is a scenario I am inventing. In early 2020 an executive at a generic company stands up in a meeting and says, “Hey team, exenatide is off patent, let’s file.” An analyst builds the model. The model says that if they win, they will own a large share of the exenatide market. Someone asks how big the exenatide market will be by the time they launch. The analyst updates the model. The model now says they will own 100% of a market whose brand has been discontinued, which is a very impressive share of not very much. The executive asks if they can be first-to-file on nothing. The analyst says that is, technically, the easiest exclusivity anyone has ever won.

I don’t know if any meeting like that happened. But the incentive it describes is real, and it explains why the first molecule off patent was not the first molecule to get a celebrated generic.

What the first generic GLP-1 actually was

The honor went to liraglutide, the drug in Victoza and Saxenda. DiaTribe described Teva’s June 24, 2024 product as “the first-ever US generic GLP-1 drug,” an authorized generic of Victoza launched under a 2019 patent settlement with Novo Nordisk. Hikma then got FDA approval for the first traditional, non-authorized generic liraglutide on December 23, 2024, and launched it in early 2025. On August 28, 2025, Teva launched a generic Saxenda, which Teva called “the first-ever generic GLP-1 indicated for weight loss in the US.” (The site has a whole separate piece on generic Victoza, so I will stop there.)

Notice what the Teva launch was. It was not a patent dying of old age and a generic rushing in. It was a settlement signed in 2019, five years ahead. The first generic GLP-1 was, in a meaningful way, scheduled. The brand company agreed when it would face competition, and on what terms. That is a very orderly way to lose a monopoly. (Most monopolies would like to lose this way, if they have to lose at all.)

Why a generic needs a brand to be generic of

Let the record reflect the following proposition, which I offer with the full weight of the doctrine: a generic drug is a copy, and a copy presupposes an original. Absent an original, the thing one is producing is not a generic but, strictly speaking, a drug.

That sounds trivial, and it is, but it is the point. The whole generic system is built around referring back to a brand. Even the language is relational. In the EU, the European Medicines Agency says generics can only be marketed once “the marketing protection of the reference product has expired, which is usually 10 or 11 years” from first authorization. The reference product is the anchor. When AstraZeneca discontinued both exenatide brands, the anchor was, in the source’s word, eliminated.

Why did AstraZeneca do it? The sources do not say. One reading is the boring one: the molecule is old, newer GLP-1s exist, and a company does not keep making a product nobody is asking for. The other reading is that a brand with no patents left and a generic future ahead of it has less reason to stick around and defend a shrinking price. Both readings fit the dates. I can’t pick between them.

Either way, the withdrawal arrived about two months after the first generic GLP-1 launched, which was a timely exit. Maybe just in the calendar sense.

What older molecules tell you about the newer ones

The exenatide story is a useful corrective to the idea that patent expiry is a price event. It is a permission event. Whether it becomes a price event depends on who wants to make the copy, how much the copy costs to make and approve, and whether the original is still worth copying.

That last part matters for how big the discount gets, too. One source estimates that US peptide generics and biosimilars “typically achieve only” 15 to 40% price reductions versus the reference product, compared with 80 to 90% for small-molecule generics, because the approval pathway is more expensive. Treat that as one estimate rather than a law of nature. (Laws of nature in drug pricing are rare, and the ones that exist are usually patented.) But if it is roughly right, it means even the GLP-1s that do get copied will not collapse in price the way an old blood pressure pill does. That’s fine as an expectation. It is just not the cliff people picture.

Now compare semaglutide, which is the molecule everyone actually cares about. Health Canada approved Dr. Reddy’s generic semaglutide on April 28, 2026, with eight other submissions under review at the time. Brazil’s core patent expired March 20, 2026 and its first generic approval followed in May. South Africa got a launch in August 2026 with 13 more applications pending. China, meanwhile, rewards the first successful patent challenger with 12 months of market exclusivity, and VCBeat says that “first generic” status there establishes a position that is “difficult for competitors to shake.” That is what a fought-over molecule looks like. Lots of filers, lots of countries, lots of lawyers or whatever.

Exenatide got none of that crowd. It is the Super Bowl ticket bought for the year after the team relocated. Technically valid. Nobody in the stands.

The pattern, anyway, is that the race to copy a drug is a measure of how much people still want the original. Extend that one step and you get an uncomfortable test for the newer drugs: the clearest sign that semaglutide has fully gone generic will not be a pile of approvals but a short notice, years from now, saying its maker has stopped making it.